An update on the safety of nivolumab for the treatment of advanced melanoma

References

• Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014 Sep;2(9):846–856.
   PubMed Web of Science ®Google Scholar
• Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019 Dec 4;7(1):341.
   PubMed Web of Science ®Google Scholar
• Upadhrasta S, Elias H, Patel K, et al. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic diseases and Translational Medicine. 2019 Mar;5(1):6–14.
   PubMedGoogle Scholar
• Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.
   Web of Science ®Google Scholar
• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016 Apr;27(4):559–574.
   PubMed Web of Science ®Google Scholar
• Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57–75.
   PubMed Web of Science ®Google Scholar
• Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264–iv266..
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018 Jun 10;36(17):1714–1768.
   PubMed Web of Science ®Google Scholar
• Kamińska-Winciorek G, Cybulska-Stopa B, Ługowska I, et al. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. Adv Dermatol Allergology/Postępy Dermatologii i Alergologii. 2019;36(4):382–391.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017 Nov 21;5(1):95.
   PubMed Web of Science ®Google Scholar
• Girotra M, Hansen A, Farooki A, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectrum. 2018 Jul;2(3):pky021.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Bingham CO 3rd, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1751–1763.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017 Mar;35(7):785–792.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 Apr 1;32(10):1020–1030.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167–3175.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017 Oct 1;28(10):2377–2385.
   PubMed Web of Science ®Google Scholar
• Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018 Nov 1;29(11):2208–2213..
   PubMed Web of Science ®Google Scholar
• Bi Y, Liu J, Furmanski B, et al. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Ann Oncol. 2019 Apr 1;30(4):644–651.
   PubMed Web of Science ®Google Scholar
• Bocquet-Tremoureux S, Scharbarg E, Nguyen JM, et al. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. Eur J Dermatol. 2019 Jun 1;29(3):315–321.
   PubMed Web of Science ®Google Scholar
• Arheden A, Skalenius J, Bjursten S, et al. Real-world data on PD-1 inhibitor therapy in metastatic melanoma. Acta Oncol. 2019 Jul;58(7):962–966.
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Rutkowski P. Summary of immunotherapy efficacy ordered in accordance with drug reimbursment guidelines in melanoma patients. Oncol Clin Pract. 2020;16 ( ([aheadof print])). doi:10.5603/OCP.2020.0004
   Google Scholar
• Parakh S, Randhawa M, Nguyen B, et al. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. Asia Pac J Clin Oncol. 2019 Feb;15(1):26–30.
   PubMed Web of Science ®Google Scholar
• Rawa T, Reguła J. Management of gastrointestinal toxicity from nivolumab therapy. Oncol Clin Pract. 2017;13(5):225–229.
   Web of Science ®Google Scholar
• Słowińska M, Maciąg A, Rozmus N, et al. Management of dermatological adverse events during nivolumab treatment. Oncol Clin Pract. 2017;13(6):301–307.
   Google Scholar
• Stelmachowska-Banaś M, Zgliczyński W. The management of nivolumab-induced endocrine immune-related adverse events. Oncol Clin Pract. 2017;13(6):295–300.
   Google Scholar
• Knetki-Wróblewska M, Kowalski DM. Management of nivolumab-induced pulmonary toxicity — pneumonitis. Oncol Clin Pract. 2018;14(1):35–39.
   Web of Science ®Google Scholar
• Logan IT, Zaman S, Hussein L, et al. Combination therapy of ipilimumab and nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a patient with metastatic melanoma: a case report and literature review. J Immunother. 2020 Apr;43(3):89–92.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res off J Am Assoc Cancer Res. 2016 Dec 15;22(24):6051–6060.
   PubMed Web of Science ®Google Scholar
• Delaunay M, Prevot G, Collot S, et al. Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev. 2019 Dec 31;28(154):154.
   Web of Science ®Google Scholar
• Suozzi KC, Stahl M, Ko CJ, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports. 2016 May;2(3):264–268.
   PubMedGoogle Scholar
• Bernheim A, Mei X, Huang M, et al. Chest CT findings in Coronavirus Disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020 Feb;20:200463.
   Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016 Nov 3;375(18):1749–1755.
   PubMed Web of Science ®Google Scholar
• Tadokoro T, Keshino E, Makiyama A, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016;9(10):Oct.
   Web of Science ®Google Scholar
• Martin Huertas R, Saavedra Serrano C, Perna C, et al. Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Res. 2019;11:4541–4548.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Mar 10;391(10124):933.
   PubMed Web of Science ®Google Scholar
• Mohn N, Beutel G, Gutzmer R, et al. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook. J Clin Med. 2019 Oct 24;8(11):11.
   Web of Science ®Google Scholar
• Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J Clin Oncol. 2016 Sep;46(9):875–878.
   PubMed Web of Science ®Google Scholar
• Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016 Jan;46(1):86–88.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017 Jun;22(6):709–718.
   PubMed Web of Science ®Google Scholar
• Haikal A, Borba E, Khaja T, et al. Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review. Avicenna J Med. 2018 Jan-Mar;8(1):34–36.
   PubMedGoogle Scholar
• Benfaremo D, Manfredi L, Luchetti MM, et al. Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. Curr Drug Saf. 2018;13(3):150–164.
   PubMed Web of Science ®Google Scholar
• Kong BY, Micklethwaite KP, Swaminathan S, et al. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016 Apr;26(2):202–204.
   PubMed Web of Science ®Google Scholar
• Hantel A, Gabster B, Cheng JX, et al. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 Jul 16;6(1):73.
   PubMedGoogle Scholar
• Neilan TG, Rothenberg ML, Amiri-Kordestani L, et al. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist. 2018 Aug;23(8):874–878.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320–330..
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated braf wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019 Feb 1;5(2):187–194.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Ascierto PA, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol. 2016 Oct;27(10):1940–1946.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480–1492.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Shah R, Gupte-Singh K, et al. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. Qual Life Res. 2019 Jan;28(1):109–119.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019 Oct 17;381(16):1535–1546..
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 5;377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol. 2018 Jan 1;4(1):98–101.
   PubMed Web of Science ®Google Scholar
• Xu H, Tan P, Ai J, et al. Antitumor activity and treatment-related toxicity associated with nivolumab plus ipilimumab in advanced malignancies: a systematic review and meta-analysis. Front Pharmacol. 2019;10:1300.
   PubMed Web of Science ®Google Scholar
• Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019 Sep;119:168–178.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019 Nov;121:144–153.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ascierto PA, Haanen JBAG, et al. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): results from a phase II study (CheckMate 172). J Clin Oncol. 2017;35(15_suppl):9524–9525.
   Google Scholar
• D’Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017 Jan 10;35(2):226–235.
   PubMed Web of Science ®Google Scholar
• Nomura M, Oze I, Masuishi T, et al. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. Int J Clin Oncol. 2020 Jan;14. https://doi.org/10.1007/s10147-020-01618-9
   Google Scholar
• Napierała MJ, Czarnecka AM. Mucosal melanoma — clinical presentation and treatment based on a case series. Oncol Clin Pract. 2019;15(4):223–230.
   Web of Science ®Google Scholar
• Elias R, Giobbie-Hurder A, McCleary NJ, et al. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018 Apr 4;6(1):26.
   PubMed Web of Science ®Google Scholar
• Freeman M, Weber J. Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma. J Immunother Cancer. 2015;3(Suppl 2):P133.
   Google Scholar
• Ibrahim T, Mateus C, Baz M, et al. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. Cancer Immunol Immunother. 2018 Oct;67(10):1571–1578.
   PubMed Web of Science ®Google Scholar
• Betof AS, Nipp RD, Giobbie-Hurder A, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017 Aug;22(8):963–971.
   PubMed Web of Science ®Google Scholar
• Cybulska-Stopa B, Ługowska I, Jagodzińska-Mucha P, et al. Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study. Postepy Dermatol Alergol. 2019;36(5):566–571.
   PubMed Web of Science ®Google Scholar
• Archibald WJ, Victor AI, Strawderman MS, et al. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: the Wilmot Cancer Institute experience. J Geriatr Oncol. 2020 Apr;11(3):496–502.
   PubMedGoogle Scholar
• Xia X, Chen W, McDermott J, et al. Molecular and phenotypic biomarkers of aging. F1000Res. 2017;6:860.
   PubMedGoogle Scholar
• Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19(5):672–681.
   PubMed Web of Science ®Google Scholar
• Gonzalez M, Hong AM, Carlino MS, et al. A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial). J Clin Oncol. 2019;37(15_suppl):TPS9600–TPS9600.
   Google Scholar
• Minniti G, Anzellini D, Reverberi C, et al. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. J Immunother Cancer. 2019 Apr 11;7(1):102.
   PubMedGoogle Scholar
• Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of melanoma metastases in the brain. Nowotwory. J Oncol. 2019;69(3–4):86–96.
   Google Scholar
• Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of brain metastases in melanoma. Oncol Clin Pract. 2019;15:1.
   PubMed Web of Science ®Google Scholar
• Placzke J, Teterycz P, Lugowska I, et al. The analysis of current treatment outcomes in melanoma patients with brain metastases. Ann Oncol. 2019;30(Supplement_5):1362P.
   Google Scholar
• Spałek M, Czarnecka AM. The role of radiotherapy in melanoma. Oncol Clin Pract. 2019;15(6):310–319.
   Web of Science ®Google Scholar
• Ma Q, Shilkrut M, Zhao Z, et al. Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. BMC Cancer. 2018 Feb 6;18(1):145.
   PubMedGoogle Scholar
• Kageyama SI, Yamaguchi S, Ito S, et al. A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis. Int cancer conf J. 2016 Oct; 54:192–196.
   PubMed Web of Science ®Google Scholar
• Agrawal Y, Howard JFJ, Collichio F. Management of myasthenia gravis without significant exacerbation during nivolumab therapy for metastatic melanoma. Ann Clin Oncol. 2019;2(2):4–5.
   Google Scholar
• Damsky W, Jilaveanu L, Turner N, et al. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J Immunother Cancer. 2019 Jun 14;7(1):153.
   PubMedGoogle Scholar
• Starobinets H, Ye J, Broz M, et al. Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. J Clin Invest. 2016 Dec 1;126(12):4417–4429.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017 Feb 1;28(2):368–376.
   PubMed Web of Science ®Google Scholar
• Phillips CM, Burke WA, Shechter A, et al. Reliability of dermatology teleconsultations with the use of teleconferencing technology. J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):398–402.
   PubMed Web of Science ®Google Scholar
• McDougall JA, Ferucci ED, Glover J, et al. Telerheumatology: a systematic review. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1546–1557.
   PubMed Web of Science ®Google Scholar
• Plazzotta F, Sommer JA, Marquez Fosser SN, et al. Asynchronous dermatology teleconsultations using a personal health record. Stud Health Technol Inform. 2018;247:690–694.
   PubMedGoogle Scholar
• Indini A, Di Guardo L, Cimminiello C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019 Feb;145(2):511–521.
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res off J Am Assoc Cancer Res. 2016 Feb 15;22(4):886–894.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019 Nov 15;7(1):306.
   PubMed Web of Science ®Google Scholar
• Pan EY, Merl MY, Lin K. The impact of corticosteroid use during anti-PD1 treatment. J Oncol Pharm Pract. 2019 Sep;7:1078155219872786.
   Google Scholar
• Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018 Feb;6(2):CD011123.
   Google Scholar
• Koseła H, Nivolumab RP. perspectives in cancer treatment. Oncol Clin Pract. 2016;12(2):52–62.
   Web of Science ®Google Scholar
• Chai QQ, Du JY, Zhu J, et al. The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non-small cell lung cancer and melanoma: network meta-analysis and systematic review. Front Pharmacol. 2019;10:1260.
   PubMed Web of Science ®Google Scholar
• Tie Y, Ma X, Zhu C, et al. Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. Int J Cancer. 2017 Feb 15;140(4):948–958.
   PubMed Web of Science ®Google Scholar
• Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:190–209.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:210–225.
   PubMed Web of Science ®Google Scholar
• Koppolu V, Rekha Vasigala VK. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther. 2018 Oct-Dec;14(6):1167–1175.
   PubMed Web of Science ®Google Scholar
• Kahler KC, Blome C, Forschner A, et al. The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. Oncotarget. 2018 May 25;9(40):26217–26225.
   PubMedGoogle Scholar
• Middleton MR, Atkins MB, Amos K, et al. Societal preferences for adjuvant melanoma health states: UK and Australia. BMC Cancer. 2017 Oct 17;17(1):689.
   PubMedGoogle Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage iii or iv melanoma. N Engl J Med. 2017 Nov 9;377(19):1824–1835..
   PubMed Web of Science ®Google Scholar
• Mandala M, Merelli B, Indriolo A, et al. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. Eur J Cancer. 2018 May;95:130–132.
   PubMed Web of Science ®Google Scholar
• Walter JR, Xu S, Paller AS, et al. Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: fertility risk of food and drug administration-approved systemic therapies. J Am Acad Dermatol. 2016 Sep;75(3):528–534.
   PubMed Web of Science ®Google Scholar
• Faje A, Reynolds K, Zubiri L, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep;181(3):211–219.
   PubMed Web of Science ®Google Scholar
• Benz KS, Maruf M, Duregon E, et al. Testicular histopathology after immunotherapy for metastatic melanoma. J Clin Oncol. 2018;36(15_suppl):e15114–e15114.
   Web of Science ®Google Scholar
• Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 Sep;20(9):1239–1251.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017 Nov 9;377(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019 Mar 1;17(3):255–289.
   PubMed Web of Science ®Google Scholar
• Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features. Cancers (Basel). 2019 5; 11(3): Mar.
   Web of Science ®Google Scholar
• Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med. 2018 Jun;6(6):472–478.
   PubMed Web of Science ®Google Scholar
• Rutkowski P. Immunotherapy of cancer — safety issues. Oncol Clin Pract. 2018;14(1):40–42.
   Web of Science ®Google Scholar
• Gellrich FF, Schmitz M, Beissert S, et al. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J Clin Med. 2020 Jan 14;9(1):223.
   PubMed Web of Science ®Google Scholar